Loading company…
Shanghai UniXell develops stem cell therapies for tumors, rare diseases, and neurological disorders.
Shanghai UniXell develops cell therapies using human pluripotent stem cell technology, with programs targeting tumors, rare diseases, and neurological disorders such as Parkinson's disease, Alzheimer's disease, and stroke. Founded in 2021, it is based in Shanghai, China. In March 2022, it raised USD 31.5 million co-led by CDH Investments and Sherpa Venture Capital, with Fosun Pharma, TF Capital, GL Ventures, and Kunlun Capital Pte Ltd also participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in